Tech Company Financing Transactions
Eikon Therapeutics Funding Round
Eikon Therapeutics, based in Hayward, secured $350.7 million from Alexandria Venture Investments, AME Cloud Ventures and E15VC.
Transaction Overview
Company Name
Announced On
2/27/2025
Transaction Type
Venture Equity
Amount
$350,700,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D efforts. Eikon's clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3929 Point Eden Way
Hayward, CA 94545
USA
Hayward, CA 94545
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages super-resolution microscopy, a Nobel Prize-winning technology, as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of developing and bringing to market novel therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roger Perlmutter
Chief Scientific Officer
Daniel Anderson
Browse more venture capital transactions:
Prev: 2/27/2025: Claros Technologies venture capital transaction
Next: 2/27/2025: Jurimesh venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs